PolarCool develops the product PolarCap® System, which alleviates the effects of concussions. The primary customers are sports clubs and facilities in ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

PolarCool has achieved significant milestones in the integration of the PolarCap® System within European ice hockey, in particular Swedish ice hockey where the company has secured agreements across the SHL, HockeyAllsvenskan, and HockeyEttan. Forshaga IF, will incorporate PolarCap® into its concussion management protocols during an initial evaluation period, with the possibility of extending the collaboration into a comprehensive two-year commercial agreement. This collaboration underscores PolarCool's commitment to advancing player welfare and elevating the standards of concussion care at all levels within ice hockey.

PolarCool CEO Erik Andersson comments:

-I am happy that we are continuing to establish PolarCap® at all levels in Swedish ice hockey. The fact that the treatment can be made available to both elite and lower-level teams shows the potential for PolarCap®. We anticipate that more clubs will choose to provide the treatment as awareness of its proven benefits continues to grow.

HockeyEttan is the third tier of Swedish ice hockey and consists of a total of 40 teams. The agreement with Forshaga IF brings strategic value, even if the financial significance of individual agreements is limited.

For more information

Erik Andersson - CEO
+46 - 73860 57 00
E-mail: erik.andersson@polarcool.se

About PolarCool AB (publ)

PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.